natgillin/translations-raw huggingface dataset:
Caution should be exercised in the interpretation of these laboratory results in patients who are receiving sulfasalazine.
Pri interpretaciji teh laboratorijskih rezultatov pri bolnikih, ki prejemajo sulfasalazin, je potrebna previdnost.
You may need treatment with [Product name] during pregnancy if the potential benefit outweighs the potential risk to you and your unborn baby.
Morda boste med nosečnostjo potrebovali zdravljenje z zdravilom [ime zdravila], če morebitna korist odtehta morebitno tveganje za vas in vašega nerojenega otroka.
Epidemiological studies provide conflicting results regarding the risk of congenital malformations.
Epidemiološke študije dajejo nasprotujoče si rezultate glede tveganja za prirojene malformacije.
Interference with laboratory testing
Vpliv na laboratorijske preiskave
• redness and shedding of skin over a larger area of the body, which may be itchy or painful (exfoliative dermatitis)
• pordelost in luščenje kože na večjem predelu telesa, kar lahko srbi ali boli (eksfoliativni dermatitis)
What you need to know before you take sulfasalazine Tell your doctor if you are taking or have recently taken [Product name], or any other sulfasalazine containing products, because they may affect results of blood and urine tests.
Kaj morate vedeti, preden boste vzeli sulfasalazin Obvestite zdravnika, če jemljete ali ste pred kratkim jemali zdravilo [ime zdravila] ali katero koli drugo zdravilo, ki vsebuje sulfasalazin, ker lahko vpliva na rezultate krvnih in urinskih preiskav.
Examples of such assays may include urea, ammonia, LDH, α-HBDH and glucose.
Primeri tovrstnih testov so preiskave sečnine, amoniaka, LDH, α-HBDH in glukoze.
Women of childbearing potential should be informed about the potential risks of propylthiouracil use during pregnancy.
Ženske v rodni dobi je treba seznaniti z morebitnimi tveganji uporabe propiltiouracila med nosečnostjo.
Special warnings and precautions for use […] Overdose can unmask existing Brugada syndrome.
Posebna opozorila in previdnostni ukrepi […] Preveliko odmerjanje lahko razkrije obstoječi Brugadov sindrom.
Sulfasalazine or its metabolites may interfere with ultraviolet absorbance, particularly at 340 nm, and may cause interference with some laboratory assays that use NAD(H) or NADP(H) to measure ultraviolet absorbance around that wavelength.
Sulfasalazin ali njegovi presnovki lahko vplivajo na absorbanco ultravijolične svetlobe, zlasti pri 340 nm, in lahko povzročajo motnje nekaterih laboratorijskih testov, ki za merjenje absorbance ultravijolične svetlobe okoli te valovne dolžine uporabljajo NAD(H) ali NADP(H).
Frequency ‘not known': Drug reaction with eosinophilia and systemic symptoms (DRESS)
Pogostnost „neznani“: Reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS)
Fertility, pregnancy and lactation Women of childbearing potential
Plodnost, nosečnost in dojenje
The potential of [Product name] to cause harm to an unborn baby is uncertain.
Ni gotovo, ali zdravilo [ime zdravila] lahko škoduje nerojenemu otroku.
Rivaroxaban should not be used for thromboprophylaxis in patients having recently undergone transcatheter aortic valve replacement (TAVR).
Rivaroksaban se ne sme uporabljati za tromboprofilakso pri bolnikih, ki so pred kratkim prestali transkatetrsko zamenjavo aortne zaklopke (TAVR- transcatheter aortic valve replacement).
If propylthiouracil is used during pregnancy, close maternal, foetal and neonatal monitoring is recommended.
Če se propiltiouracil uporablja med nosečnostjo, je priporočeno skrbno spremljanje matere, ploda in novorojenčka.
Loperamide - Brugada syndrome in the context of abuse with loperamide (EPITT no 19379)
Loperamid - Brugadov sindrom v okviru zlorabe loperamida (št. EPITT 19379)
Tell your doctor, or seek medical attention immediately if you have the following side effects: Frequency not known (cannot be estimated from the available data): - Inflammation of the eye (uveitis) with symptoms such as eye redness, pain, sensitivity to light, runny eyes, seeing small dots or getting blurred vision
Neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov): - vnetje očesa (uveitis) s simptomi, kot so pordelost očesa, bolečina, občutljivost za svetlobo, izcedek iz oči, prikazovanje majhnih pikic ali zamegljen vid
Frequency not known: uveitis
Neznana pogostnost: uveitis
Consult with the testing laboratory regarding the methodology used.
Glede uporabljene metodologije se posvetujte z laboratorijem, kjer opravljajo preiskave.
Animal studies are insufficient with respect to reproductive toxicity.
Študije vpliva na sposobnost razmnoževanja na živalih niso zadostne.
Propylthiouracil should be administered during pregnancy at the lowest effective dose without additional administration of thyroid hormones.
Propiltiouracil med nosečnostjo je treba dajati v najmanjšem učinkovitem odmerku, brez dodajanja ščitničnih hormonov.
Propylthiouracil is able to cross the human placenta.
Propiltiouracil lahko prehaja skozi človeško placento.
[…] Overdose can unmask existing Brugada syndrome.
Preveliko odmerjanje […] Preveliko odmerjanje lahko razkrije obstoječi Brugadov sindrom.
Temozolomide - Drug reaction with eosinophilia and systemic symptoms (DRESS) (EPITT no 19332)
Temozolomid - reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS)(št. EPITT 19332)
Rivaroxaban - Premature ending of the GALILEO study in patients who have received an artificial heart valve through a transcatheter aortic valve replacement (TAVR) (EPITT no
Rivaroksaban - predčasen zaključek študije GALILEO pri bolnikih, ki so prejeli umetno srčno zaklopko s transkatetrsko zamenjavo aortne zaklopke (TAVR) (št. EPITT 19294)
It is possible that alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase-muscle/brain (CK-MB), glutamate dehydrogenase (GLDH), or thyroxine may also show interference when sulfasalazine treatment is given at high doses.
Možno je, da se med zdravljenjem z velikimi odmerki sulfasalazina motnje pokažejo tudi pri merjenju alanin-aminotransferaze (ALT), aspartat-aminotransferaze (AST), kreatin-kinaze v mišicah/možganih (CK-MB), glutamatdehidrogenaze (GLDH) ali tiroksina.
Secukinumab - Dermatitis exfoliative generalised (EPITT no 19354)
Sekukinumab - generalizirani eksfoliativni dermatitis (št. EPITT 19354)
Sulfasalazine - Interference with dihydronicotinamideadenine dinucleotide / dihydronicotinamide-adenine dinucleotide phosphate (NADH/NADP) reaction assays (EPITT no 19351)
Sulfasalazin - motnje testov z reakcijo dihidronikotinamidadenindinukleotida/dihidronikotinamidade nindinukleotidfosfata (NADH/NADP) (št. EPITT 19351)
Topiramate - Uveitis (EPITT no 19345)
Topiramat - uveitis (št. EPITT 19345)
Patients with prosthetic valves
Bolniki z umetnimi zaklopkami
Individual benefit/risk assessment is necessary before treatment with propylthiouracil during pregnancy.
Pred zdravljenjem s propiltiouracilom med nosečnostjo je potrebna individualna ocena razmerja med tveganji in koristmi.
Undesirable effects Eye disorders
Preglednica z neželenimi učinki
Overdose
Očesne bolezni
3.75 micrograms propagated in eggs ** haemagglutinin
namnožen v jajcih ** hemaglutinin
Prepandrix 3.75 µg HA1 Suspension and Emulsion for emulsion for injection
Suspenzija in emulzija za emulzijo za injiciranje
After mixing, 1 dose (0.5 ml) contains: Split influenza virus inactivated, containing antigen equivalent to: A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2)
A/Indonesia/05/2005 (H5N1) podobnemu sevu (PR8-IBCDC-RG2) 3,75 mikrogramov**
Linoladiol EstradiolEmulsion
Linoladiol EstradiolEmulsion vaginalna emulzija Dermalna uporaba,
Linoladiol N 0,1 mg/g vaginal cream
Linoladiol N 0,1 mg/g vaginal cream vaginalna krema Vaginalna uporaba,
0.01 % w/w estradiol containing medicinal products for topical use Member
Zdravila za topično uporabo, ki vsebujejo 0,01 % m/m estradiola Država članica (v EGP)
0.005 % w/w estradiol / 0.4 % w/w prednisolone containing medicinal products for topical use Member
Zdravila za topično uporabo, ki vsebujejo 0,005 % m/m estradiola/0,4 % m/m prednizolona Država članica (v EGP)
Further information on Tafinlar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Nadaljnje informacije o zdravilu Tafinlar so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Tafinlar is available as capsules (50 and 75 mg).
Zdravilo Tafinlar je na voljo v obliki kapsul (50 in 75 mg).
What measures are being taken to ensure the safe and effective use of Tafinlar?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Tafinlar?
Other information about Tafinlar
Druge informacije o zdravilu Tafinlar
Tafinlar received a marketing authorisation valid throughout the EU on 26 August 2013.
Za zdravilo Tafinlar je bilo 26. avgusta 2013 izdano dovoljenje za promet, veljavno po vsej EU.
As for all medicines, data on the use of Tafinlar are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Tafinlar stalno spremljajo.
This was based on one main study involving 250 patients, which measured how long patients lived until their disease got worse.
Ta ugotovitev je temeljila na eni glavni študiji, ki je vključevala 250 bolnikov in v kateri so merili čas preživetja bolnikov do poslabšanja bolezni.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tafinlar have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Tafinlar upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
An overview of Tafinlar and why it is authorised in the EU
Pregled zdravila Tafinlar in zakaj je odobreno v EU
The dose of Tafinlar either used alone or in combination with trametinib is 150 mg twice a day taken on an empty stomach (at least 1 hour before or 2 hours after a meal).
Odmerek zdravila Tafinlar, ki se uporablja samostojno ali v kombinaciji s trametinibom, je 150 mg dvakrat na dan na prazen želodec (vsaj eno uro pred obrokom ali dve uri po njem).
Treatment with Tafinlar must be started and supervised by a doctor experienced in the use of cancer medicines.
Zdravljenje z zdravilom Tafinlar mora uvesti in nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
What benefits of Tafinlar have been shown in studies?
Kakšne koristi zdravila Tafinlar so se pokazale v študijah?
• melanoma (a skin cancer) that has spread or cannot be removed surgically.
• melanoma (kožnega raka), ki se je razširil ali ga ni mogoče kirurško odstraniti.
Tafinlar's side effects were considered acceptable and manageable with appropriate measures.
Neželeni učinki zdravila Tafinlar veljajo za sprejemljive in jih je mogoče obvladovati z ustreznimi ukrepi.
• advanced non-small cell lung cancer.
• napredovalega nedrobnoceličnega pljučnega raka.
What is Tafinlar and what is it used for?
Kaj je zdravilo Tafinlar in za kaj se uporablja?
Side effects reported with Tafinlar are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Tafinlar, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Why is Tafinlar authorised in the EU?
Zakaj je bilo zdravilo Tafinlar odobreno v EU?
Some 40% of patients treated with the combination either died or had their disease come back after an average of about 3.5 years compared with 59% of patients receiving placebo.
Približno 40 % bolnikov, zdravljenih s kombinacijo učinkovin, je po 3,5 leta bodisi umrlo bodisi se je pri njih bolezen ponovila; med bolniki, ki so prejemali placebo, je bilo takih 59 %.
The European Medicines Agency decided that Tafinlar's benefits in cancers that carry the BRAF V600 mutation are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Tafinlar pri raku z mutacijo BRAF V600 večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
For more information about using Tafinlar, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Tafinlar glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What are the risks associated with Tafinlar?
Kakšna tveganja so povezana z zdravilom Tafinlar?
Tafinlar is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) called ‘BRAF V600'.
Tafinlar je zdravilo proti raku, ki se uporablja za zdravljenje odraslih, katerih rakave celice imajo posebno gensko mutacijo (spremembo), imenovano „BRAF V600“.
The most common side effects with Tafinlar (which may affect more than 1 in 10 people) are papilloma (warts), headache, nausea, vomiting, hyperkeratosis (thickening and toughening of the skin), hair loss, rash, joint pain, fever and tiredness.
Najpogostejši neželeni učinki zdravila Tafinlar (ki se lahko pojavijo pri več kot 1 bolniku od 10) so papilomi (bradavice), glavobol, navzeja (slabost), bruhanje, hiperkeratoza (odebelitev in otrdelost kože), izpadanje las, izpuščaji, bolečine v sklepih, povišana telesna temperatura in utrujenost.
The Agency also found it to be of benefit in patients with advanced melanoma that had been removed surgically.
Ugotovila je tudi, da je koristno pri bolnikih z napredovalim melanomom, ki so ga kirurško odstranili.
Tafinlar can be continued for as long as the patient benefits from it. After surgery for advanced melanoma, treatment is normally continued for 12 months unless the disease comes back.
Po kirurškem posegu zaradi napredovalega melanoma se zdravljenje običajno nadaljuje 12 mesecev, razen če se bolezen ponovi.
Two additional studies on melanoma that had spread to other parts of the body or could not be removed surgically looked at using the combination of Tafinlar with trametinib.
V dveh dodatnih študijah pri melanomu, ki se je razširil na druge dele telesa ali ga ni bilo mogoče kirurško odstraniti, so proučevali uporabo kombinacije zdravila Tafinlar in trametiniba.
The Agency considered that Tafinlar when used alone or in combination with trametinib had shown clinically relevant benefit in patients with advanced non-small cell lung cancer or with melanoma that had spread or could not be removed surgically.
Menila je, da je zdravilo Tafinlar, kadar se je uporabljalo samostojno ali v kombinaciji s trametinibom, izkazalo klinično pomembne koristi pri bolnikih z napredovalim nedrobnoceličnim pljučnim rakom ali melanomom, ki se je razširil ali ga ni mogoče kirurško odstraniti.
In melanoma and non-small cell lung cancer with the BRAF V600 mutation, the abnormal form of BRAF plays a role in the development of the cancer by allowing uncontrolled division of the tumour cells.
Pri melanomu in nedrobnoceličnem pljučnem raku z mutacijo BRAF V600 nenormalna oblika beljakovine BRAF vpliva na razvoj raka tako, da omogoča nenadzorovano deljenje tumorskih celic.
Patients given the combination lived for 11 months without their disease worsening, compared with 8.8 months for those given Tafinlar alone.
Bolniki, ki so prejemali kombinacijo učinkovin, so brez poslabšanja bolezni živeli 11 mesecev, bolniki, ki so prejemali samo zdravilo Tafinlar, pa 8,8 meseca.
When Tafinlar is taken in combination with trametinib, the most common side effects (which may affect more than 1 in 5 people) are fever, tiredness, nausea, chills, headache, diarrhoea, vomiting, joint pain and rash.
Kadar se zdravilo Tafinlar jemlje v kombinaciji s trametinibom, so najpogostejši neželeni učinki (ki se lahko pojavijo pri več kot 1 bolniku od 5) povišana telesna temperatura, utrujenost, navzeja, mrzlica, glavobol, driska, bruhanje, bolečine v sklepih in izpuščaj.
In a study involving 870 patients with stage III melanoma that had been removed surgically, the combination of Tafinlar and trametinib given for 1 year was compared with placebo (a dummy treatment).
V študiji, ki je vključevala 870 bolnikov z melanomom v III. stadiju, ki so ga kirurško odstranili, so kombinacijo zdravila Tafinlar in trametiniba, ki so jo dajali eno leto, primerjali s placebom (zdravilom brez učinkovine).
Tafinlar is used on its own or in combination with another cancer medicine, trametinib;
Zdravilo Tafinlar se uporablja samostojno ali v kombinaciji z drugim zdravilom za zdravljenje raka, trametinibom;
Patients taking Tafinlar lived on average 6.9 months before the disease got worse, compared with 2.7 months in patients given dacarbazine.
Bolniki, ki so jemali zdravilo Tafinlar, so brez poslabšanja bolezni živeli povprečno 6,9 meseca, bolniki, ki so jemali dakarbazin, pa 2,7 meseca.
Tafinlar contains the active substance dabrafenib.
Zdravilo Tafinlar vsebuje učinkovino dabrafenib.
For the full list of side effects and restrictions with Tafinlar, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Tafinlar glejte navodilo za uporabo.
In a second study involving 704 patients, Tafinlar with trametinib was compared with another medicine for melanoma, vemurafenib.
V drugi študiji, v kateri so sodelovali 704 bolniki, so zdravilo Tafinlar v kombinaciji s trametinibom primerjali z drugim zdravilom za zdravljenje melanoma, vemurafenibom.
The use of Tafinlar and trametinib led to a response in over 60% of the patients, compared with 23% of patients using Tafinlar alone.
Do odziva je prišlo pri več kot 60 % bolnikov, ki so jemali zdravilo Tafinlar in trametinib, ter pri 23 % bolnikov, ki so jemali zdravilo Tafinlar kot samostojno zdravilo.
In one main study, 171 patients with non-small cell lung cancer received either Tafinlar combined with trametinib or Tafinlar alone.
V eni glavni študiji je 171 bolnikov z nedrobnoceličnim pljučnim rakom prejemalo bodisi zdravilo Tafinlar v kombinaciji s trametinibom bodisi samo zdravilo Tafinlar.
The active substance in Tafinlar, dabrafenib, works by blocking BRAF, a protein involved in stimulating cell division.
Učinkovina v zdravilu Tafinlar, dabrafenib, deluje tako, da zavira beljakovino BRAF, ki sodeluje pri spodbujanju delitve celic.
By blocking the action of the abnormal BRAF, Tafinlar helps to slow down the growth and spread of the cancer.
Zdravilo Tafinlar z zaviranjem delovanja nenormalne beljakovine BRAF prispeva k upočasnitvi rasti in širjenja raka.
Tafinlar has been studied in patients whose cancer had the BRAF V600 mutation.
Zdravilo Tafinlar so proučevali pri bolnikih, katerih rakave celice so imele mutacijo BRAF V600.
In one study 423 patients were given either the combination or Tafinlar alone.
V eni študiji je 423 bolnikov prejelo bodisi kombinacijo učinkovin bodisi zdravilo Tafinlar kot samostojno zdravljenje.
Patients given the combination lived 25.6 months on average, versus 18 months with vemurafenib.
Bolniki, ki so prejemali kombinacijo učinkovin, so povprečno živeli 25,6 meseca, bolniki, ki so prejemali vemurafenib, pa 18 mesecev.
How does Tafinlar work?
Kako zdravilo Tafinlar deluje?
How is Tafinlar used?
Kako se zdravilo Tafinlar uporablja?
Treatment may need to be interrupted or stopped, or the dose reduced, if certain side effects occur.
Če se pri bolniku pojavijo nekateri neželeni učinki, bo morda treba začasno ali trajno prekiniti zdravljenje ali zmanjšati odmerek.
It is used for the treatment of:
Zdravilo Tafinlar se uporablja za zdravljenje:
It is used in combination with trametinib.
Zdravilo Tafinlar se uporablja v kombinaciji s trametinibom.
• advanced (stage III) melanoma after surgery for it. Tafinlar is used in combination with trametinib;
• napredovalega melanoma (v III. stadiju) po prestanem kirurškem posegu.
Tafinlar was more effective than the cancer medicine dacarbazine at controlling melanoma that had spread to other parts of the body or could not be removed surgically.
Zdravilo Tafinlar je bilo pri nadziranju melanoma, ki se je razširil na druge dele telesa ali ga ni bilo mogoče kirurško odstraniti, učinkovitejše od druge učinkovine za zdravljenje raka, imenovane dakarbazin.
Strength Pharmaceutical form Route of administration
(Izmišljeno) ime Jakost Farmacevtska oblika Pot uporabe
Take the remaining doses at the correct time.
Preostale odmerke vzemite ob pravilnem času.
30 months 90 days after first opening.
90 dni po prvem odprtju.
Each double-blind study period lasted 2 weeks.
Vsako dvojno slepo obdobje študije je trajalo 2 tedna.
Unknown a)
Neznana a)
Take it as soon as you remember unless it is nearly time to take the next dose.
Vzemite ga takoj, ko se spomnite, razen če je že skoraj čas, da vzamete naslednji odmerek.
Dosing this medicinal product more than 5 times per day is not recommended.
Odmerjanje tega zdravila več kot 5-krat na dan ni priporočljivo.
All efficacy data is based on 84 patients who completed the study with the exception of patient diary data which is based on 83.
Vsi podatki o učinkovitosti temeljijo na 84 bolnikih, ki so končali študijo, razen podatkov o prehrani bolnikov, ki temeljijo na podatkih 83 bolnikov.
It cannot be excluded that heating may change the properties of the medicinal product.
Ni mogoče izključiti, da segrevanje lahko spremeni lastnosti zdravila.
Data in the ASCEND-PD study were analysed using a standard mixed-model analysis of variance.
Podatke v študiji ASCEND-PD so analizirali s standardnim mešanim modelom analize variance.
This is because the medicine may affect the results of some tests.
To je zato, ker to zdravilo lahko vpliva na rezultate nekaterih preiskav.
In between these periods, all patients received open-label Numient treatment for 1 week.
Med temi obdobji so vsi bolniki 1 teden prejemali odprto zdravljenje z zdravilom Numient.
The daily dose must be determined by careful titration.
Dnevni odmerek je treba določiti s previdnim titriranjem.
Frequencies are defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Pogostnost je opredeljena kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), neznana pogostost (ni mogoče oceniti iz razpoložljivih podatkov).
This reaction does not change upon boiling the urine sample.
Ta reakcija se ne spremeni po segrevanju vzorca urina.
However, your doctor may decide to give you Numient if the expected benefits of treatment outweigh possible risks to the unborn child.
Kljub temu se vaš zdravnik lahko odloči, da vam bo predpisal zdravilo Numient, če pričakovane koristi zdravljenja odtehtajo morebitno tveganje za nerojenega otroka.
If your diet contains too much protein (meat, eggs, milk, cheese), Numient may not work as well as it should.
Če vaša prehrana vsebuje preveč beljakovin (mesa, jajc, mleka, sira), zdravilo Numient morda ne bo delovalo, kot bi moralo.
Main study results are summarized in Table 5.
Rezultati Glavni rezultati študije so povzeti v preglednici 5.
These differences are primarily explained by the lower body weight in females.
Te razlike je mogoče razložiti z manjšo telesno maso pri ženskah.
In the ADVANCE-PD study, the Clinical Global Impression of Change was also assessed.
Pri študiji ADVANCE-PD so ocenili tudi klinični globalni vtis o spremembi (Clinical Global Impression of Change).
Pyridoxine is not effective in reversing the actions of this combination medicinal product.
Piridoksin ni učinkovit pri odpravljanju učinkov tega kombiniranega zdravila.
Do not use this medicine after the expiry date which is stated on the carton and on the bottle after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na steklenici poleg oznake »EXP«.
What Numient is and what it is used for
Kaj je zdravilo Numient in za kaj ga uporabljamo
You must swallow your capsules whole.
Kapsule morate pogoltniti cele.
Numient with food and drink
Zdravilo Numient skupaj s hrano in pijačo